Blood Pressure Disorders, Chronic Kidney Disease, Hemodialysis, Inflammation, Ischemia Preconditioning
Conditions
Keywords
Hemodialysis, ischemia preconditioning
Brief summary
The aim of our study is to evaluate the impact of repeated episodes of ischemic quenching on changes in blood pressure, heart rate and laboratory parameters of inflammation in patients with kidney diseases. There is credible evidence that intentionally producing periods of ischemia provides protection of the myocardium and blood vessels against subsequent ischemic injury. The examination will be performed during hospitalization in the Department of Nephrology, Hypertension, Transplantology and Internal Diseases and will last 4 days. On the first day, blood pressure will be measured using an automatic blood pressure monitor, radial artery pulse, blood saturation will be measured using a pulse oximeter, and approximately 6 ml of venous blood will be collected from the elbow bend area for laboratory tests. Then, compression of the lower limb below the knee will be performed using a blood pressure cuff. Four 5-minute cycles of inflation and deflation of the cuff will be performed. The pressure on the lower limb will be repeated on the next two days. On the last day of the examination, blood pressure, heart rate and blood saturation will be measured again, and approximately 6 ml of venous blood will be collected again for laboratory tests.
Interventions
OTHERPreconditioning with control ischemic episodes
4 cycles of 5-minute inflation and deflation using a sphygmomanometer cuff at a pressure of 30 mmHg above the systolic value through three consecutive days
Sponsors
Medical University of Lodz
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* obtaining the patient's voluntary, informed consent to participate in the experiment, * chronic kidney disease in stages G1-G5, * women and men over 18 years of age. * failure to meet the qualification criteria for participation in the study, * consciousness disorders, * heart failure (NYHA IV), * severe anemia (Hb concentration\<8g/dL), * features of muscle cell damage (e.g. rhabdomyolysis), * peripheral circulation disorders, peripheral vascular diseases.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of changes of parameter: Measurement of SIRT-1 [ng/] | 7 days | Measurement of SIRT-1 \[ng/\] at the beginning and 7 days |
| Assessment of changes of parameter blood saturation [%]. | 7 days | at the beginning and 7 days |
| Assessment of IL-6 | 7 days | Measurement of IL-6 \[ng/ml\] at the beginning and 7 days. |
| Assessment of Blood pressure | 7 days | Blood pressure \[mmHg\] will be checked at the beginning and 7 days |
| Assessment of heart beat/min | 7 days | will be checked at the beginning and 7 days |
Countries
Poland
Contacts
CONTACTMichał Nowicki, Professor
CONTACTKatarzyna Pęczek-Bartyzel, MD PhD
Outcome results
None listed